Meeting Details - The first meeting of the third Supervisory Board of Hangzhou Anjisi Medical Technology Co., Ltd. was held, with all three supervisors present, confirming the legality and validity of the meeting [1][2] - The meeting was convened following the election of the non-employee representative members at the annual shareholders' meeting [1] Resolutions Passed - The Supervisory Board approved the election of Mr. Shi Baoming as the chairman of the third Supervisory Board, with his term starting from the date of this meeting until the end of the current board's term [1][2] - The voting results were unanimous, with 3 votes in favor, 0 against, and 0 abstentions [2]

Core Viewpoint - The shareholders' meeting of Hangzhou Anjisi Medical Technology Co., Ltd. was held on May 16, 2025, with all proposed resolutions approved by the shareholders [1][6]. Meeting Details - The meeting took place at Room 302, 3rd Floor, No. 389 Xingzhong Road, Linping District, Hangzhou [1]. - A total of 48 ordinary shareholders attended the meeting, holding 57,830,094 voting rights, which accounted for 71.77% of the company's total voting rights [1]. Voting Results - All non-cumulative voting proposals were approved, with the following voting results: - Proposal 1: 57,694,589 votes in favor (99.77%), 121,105 votes against (0.21%), and 14,400 abstentions (0.03%) [2]. - Proposal 2: 57,691,389 votes in favor (99.76%), 124,305 votes against (0.21%), and 14,400 abstentions (0.03%) [2]. - Proposal 3: 57,692,589 votes in favor (99.76%), 137,505 votes against (0.24%), and no abstentions [3]. Election of Directors - The election of directors was conducted with the following results: - Zhang Cheng was elected with 55,363,070 votes (95.73%) [3]. - Zhang Qianyi was elected with 55,363,071 votes (95.73%) [3]. - Shen Menghui was elected with 55,392,711 votes (95.79%) [4]. - Feng Yang was elected with 55,392,710 votes (95.79%) [4]. Legal Compliance - The meeting and voting procedures complied with the Company Law and the company's articles of association, ensuring the legality and validity of the resolutions passed [6].

Core Viewpoint - The legal opinion provided by Beijing Deheng (Hangzhou) Law Firm confirms the legality of the 2024 annual general meeting of Hangzhou Anjisi Medical Technology Co., Ltd, ensuring compliance with relevant laws and regulations [1][3][12] Group 1: Meeting Procedures - The annual general meeting is scheduled for May 16, 2025, with proper notification published on the Shanghai Stock Exchange and other designated media [3][4] - The meeting will utilize a combination of on-site and online voting methods, with specific timeframes for both [4][5] - The meeting's procedures for convening and conducting are deemed compliant with the Company Law and other relevant regulations [4][5] Group 2: Attendance and Voting - The record date for shareholder attendance is set for May 12, 2025, with 48 shareholders and their proxies representing 57,830,094 shares, accounting for 71.7701% of the total voting shares [4][5] - The voting results indicate a high level of agreement among shareholders, with significant support from minority investors [6][7][8] Group 3: Voting Results - A total of 18 agenda items were voted on, with the majority receiving overwhelming support, including votes from minority shareholders [5][6][9] - Specific resolutions, such as the election of directors and supervisors, received substantial approval, reflecting strong shareholder confidence [10][11] Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including the convening, attendance, and voting procedures, are in accordance with the Company Law and the company's articles of association, rendering the resolutions valid [12]

Core Viewpoint - The company has completed the election of its third board of directors and supervisory board, along with the appointment of senior management personnel, marking a significant governance transition [1][3]. Board of Directors Election - The third board of directors consists of two non-independent directors, two independent directors, and one employee representative director, with a term of three years starting from the approval date of the 2024 annual general meeting [1][2]. - Zhang Cheng was elected as the chairman of the board, and various specialized committees were formed, including the audit committee, nomination committee, compensation and assessment committee, and strategic committee [2]. Supervisory Board Election - The third supervisory board includes two non-employee representative supervisors and one employee representative supervisor, with a term of three years starting from the approval date of the 2024 annual general meeting [3][4]. - Shi Baoming was elected as the chairman of the supervisory board [4]. Senior Management Appointments - The company appointed a new general manager, deputy general managers, a financial director, and a board secretary, all of whom meet the qualifications required by relevant laws and regulations [4][5]. - The board secretary, Zhang Qinhua, holds the necessary qualifications to perform his duties effectively [4][5]. Securities Affairs Representative Appointment - Du Xinyu was appointed as the securities affairs representative, assisting the board secretary with daily securities matters [5][10]. Departure of Previous Board Members - Following the completion of the election, three previous board members, including Sheng Yueyuan and independent directors Wu Jianhai and Xia Lianan, have completed their terms and are no longer serving on the board [6][7].

Core Viewpoint - The company has completed a capital increase for its subsidiary, Hang An Medical Technology, to implement an employee stock ownership plan, resulting in a decrease in the company's shareholding to 90.9091% [1][2]. Group 1: Transaction Overview - Hang An Medical has introduced an employee stock ownership platform, Hangzhou Dingliang Enterprise Management Partnership, through a capital increase of 5 million yuan, with the company waiving its preferential subscription rights [1]. - The capital increase has been completed, and the company's shareholding in Hang An Medical has decreased to 90.9091%, changing its status from a wholly-owned subsidiary to a controlling subsidiary [1][2]. Group 2: Business Registration Completion - Hang An Medical has completed the business registration with the Hangzhou Linping District Market Supervision Administration and has received its business license [2]. - The registered capital of Hang An Medical is now 55 million yuan, and it operates in various medical device sectors, including the production and sale of Class II and Class III medical devices [2]. Group 3: Impact on the Listed Company - The transaction will not change the scope of the company's consolidated financial statements and will not adversely affect the company's operating results or financial condition [4].

关于全资子公司通过增资实施股权激励及公司放弃优先认 购权暨关联交易事项进展暨完成工商变更登记的公告 证券代码：688581 证券简称：安杰思 公告编号：2025-033 杭州安杰思医学科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提醒： 杭州安杰思医学科技股份有限公司（以下简称"公司"）子公司杭安医学 科技（杭州）有限公司（以下简称"杭安医学"）通过增资形式引入员工持 股平台杭州鼎亮企业管理合伙企业（有限合伙）（以下简称"杭州鼎亮"）， 公司放弃本次增资的优先认购权的事项已经公司第二届董事会第十九次会 议、第二届监事会第十五次会议审议通过。 杭安医学已于近日完成与本次增资相关的工商变更登记，公司对杭安医 学的持股比例下降至 90.9091%。杭安医学由公司全资子公司变更为公司的 控股子公司，公司合并报表范围未发生变化。 一、交易概述 为进一步落实公司的发展战略，优化子公司杭安医学的资本结构，同时建立 健全杭安医学的长效激励机制，提升杭安医学的运营及管理效率、可持续发展能 力及核心竞争力，吸引和留 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 5 月 16 日，杭州安杰思医学科技股份有限公司（以下简称"公司"） 召开 2024 年年度股东大会，选举产生了第三届董事会、监事会非职工代表成员， 与公司于 2025 年 4 月 21 日召开的职工代表大会选举产生的职工代表董事、职工 代表监事，共同组成公司第三届董事会、第三届监事会。同日，公司召开第三届 董事会第一次会议及第三届监事会第一次会议，分别选举产生了董事长、专门委 员会委员及监事会主席，并聘任第三届高级管理人员和证券事务代表。现将相关 情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 5 月 16 日，公司召开 2024 年年度股东大会，通过了《关于公司董 事会换届选举暨选举第三届董事会非独立董事的议案》《关于公司董事会换届选 举暨选举第三届董事会独立董事的议案》，选举张承先生、张千一女士为公司第 三届董事会非独立董事，选举沈梦晖先生、冯洋先生为公司第三届董事会独立董 事；2025 年 4 月 21 日，公司召开了第三届第二 ...

关于杭州安杰思医学科技股份有限公司 北京德恒（杭州）律师事务所 2024 年年度股东大会的法律意见 北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2024 年年度股东大会的 北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2024 年年度股东大会的 法律意见 电话:0571-86508080 传真:0571-87357755 邮编:310020 杭州市上城区新业路 200 号华峰国际商务大厦 10 楼 法律意见 致：杭州安杰思医学科技股份有限公司 北京德恒（杭州）律师事务所受杭州安杰思医学科技股份有限公司（以下简 称"公司"）委托，指派冯琳律师、汪节云律师（以下简称"本所律师"）出席 公司 2024 年年度股东大会（以下简称"本次股东大会"），对本次股东大会的合 法性进行见证并出具法律意见。 本法律意见根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》等 现行有效的法律、法规和规范性文件以及《杭州安杰思医学科技股份有限公司章 程》（以下简称"《公司章程》"）而出具。 为出具本法律意见，本所律师审查了 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-030 杭州安杰思医学科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 48 | | --- | --- | | 普通股股东人数 | 48 | | 2、出席会议的股东所持有的表决权数量 | 57,830,094 | | 普通股股东所持有表决权数量 | 57,830,094 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 71.7701 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 71.7701 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 （一） 股东大会召开的时间：2025 年 5 月 16 日 （二） 股东大会召开 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-031 杭州安杰思医学科技股份有限公司 第三届监事会第一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 杭州安杰思医学科技股份有限公司（以下简称"公司"）第三届监事会第一次会议于 2025 年 5 月 16 日 16 时 30 分在公司九楼会议室以现场结合通讯会议的方式召开。鉴于 公司第三届监事会非职工代表成员经同日召开的 2024 年年度股东大会选举产生，全体 监事一致同意豁免本次会议通知时限要求，并同意推选监事时百明主持，会议上已对 本次紧急会议作出说明。会议应出席监事 3 名，实际出席 3 名，会议召开符合法律法 规及《公司章程》的相关规定。会议决议合法、有效。 全体与会监事经认真审议和表决，形成以下决议： 二、监事会会议审议情况 2 经与会监事审议，做出以下决议： （一）审议通过《关于选举第三届监事会主席的议案》 监事会认为：时百明先生符合《中华人民共和国公司法》《公司章程》等相关规 定，同意选举时百明先生担任公司第三 ...